{"id":4110,"date":"2026-06-09T09:09:24","date_gmt":"2026-06-09T16:09:24","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=4110"},"modified":"2026-06-09T09:09:29","modified_gmt":"2026-06-09T16:09:29","slug":"everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/","title":{"rendered":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>MIL62 (generic name: Obinutuzumab \u03b2 Injection) has been granted clinical development and commercialization rights in the Asia-Pacific region (including Southeast Asia, India, South Korea, Australia, New Zealand, as well as Hong Kong (China), Macau (China), and Taiwan (China)) under a commercial licensing agreement announced on June 4 between Everest Medicines and Tian Guangshi. The total upfront and milestone payments under this collaboration amount to RMB 209 million.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>MIL62 is an innovative third-generation CD20 antibody drug independently developed by Tian Guangshi,<\/strong>&nbsp;which received its first marketing approval in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD). In October 2025, the New Drug Application (NDA) for MIL62 for the treatment of primary membranous nephropathy (pMN) was also granted priority review by the CDE. Additionally, MIL62 is currently being evaluated in Phase III clinical trials for indications including systemic lupus erythematosus (SLE) and follicular lymphoma (FL).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy Obinutuzumab beta<strong>&nbsp;<\/strong>online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MIL62 (generic name: Obinutuzumab \u03b2 Injection) has been granted clinical development and commercialization rights in the Asia-Pacific region (including Southeast Asia, India, South Korea, Australia, New Zealand, as well as Hong Kong (China), Macau (China), and Taiwan (China)) under a commercial licensing agreement announced on June 4 between Everest Medicines and Tian Guangshi. The total [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2851,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-4110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China<\/title>\n<meta name=\"description\" content=\"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T16:09:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T16:09:29+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/everest.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"344\" \/>\n\t<meta property=\"og:image:height\" content=\"146\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets\",\"datePublished\":\"2026-06-09T16:09:24+00:00\",\"dateModified\":\"2026-06-09T16:09:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/\"},\"wordCount\":191,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/everest.jpg\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/\",\"name\":\"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/everest.jpg\",\"datePublished\":\"2026-06-09T16:09:24+00:00\",\"dateModified\":\"2026-06-09T16:09:29+00:00\",\"description\":\"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/everest.jpg\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/everest.jpg\",\"width\":344,\"height\":146,\"caption\":\"everest medicines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China","description":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/","og_locale":"en_US","og_type":"article","og_title":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China","og_description":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-09T16:09:24+00:00","article_modified_time":"2026-06-09T16:09:29+00:00","og_image":[{"width":344,"height":146,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/everest.jpg","type":"image\/jpeg"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets","datePublished":"2026-06-09T16:09:24+00:00","dateModified":"2026-06-09T16:09:29+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/"},"wordCount":191,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/everest.jpg","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/","name":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/everest.jpg","datePublished":"2026-06-09T16:09:24+00:00","dateModified":"2026-06-09T16:09:29+00:00","description":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/everest.jpg","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/everest.jpg","width":344,"height":146,"caption":"everest medicines"},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/everest-secures-exclusive-rights-to-obinutuzumab-beta-across-key-asia-pacific-markets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=4110"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4110\/revisions"}],"predecessor-version":[{"id":4111,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4110\/revisions\/4111"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/2851"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=4110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=4110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=4110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}